Kyowa Hakko Kirin Co. Ltd, Archimedes Pharma deal

Kyowa’s ProStrakan Group plc subsidiary will acquire Archimedes from life science investor Novo A/S for L230 million ($394.4 million) in cash. Archimedes has technologies for nasal and oral drug delivery and markets products in the EU for pain, oncology and critical care, including pain product PecFent fentanyl citrate nasal spray. The specialty pharma recorded 2013 revenues of L41 million ($67.8 million).

ProStrakan markets products for oncology and oncology supportive care, including Abstral fentanyl, a sublingual mucoadhesive fentanyl. ProStrakan markets Abstral in the EU to manage breakthrough cancer pain in patients who are already receiving maintenance opioid therapy for chronic cancer pain. The company - which recorded 2013 revenues of L155 million ($256.1 million) - said the deal will grow its businesses in the U.K., France, Germany and Spain, where Archimedes has “sales and marketing infrastructure which will complement ProStrakan’s current operations.” ...